AllDocs -> cancers

A post-PSA Update on Trends in Prostate Cancer Incidence Ann Hamilton and Myles Cockburn Keck School of Medicine, USC, Los Angeles Page 2 Background 1986: FDA approved PSA test to monitor disease status in prostate cancer patients 1994: PSA test approved to aid in prostate cancer detection 1988: Use of PSA for screening increasing dramatically Page 3 Surveillance, Epidemiology, and End Results (SEER) Program (www.seer. cancer .gov) SEER*Stat Database: Mortality - All COD, Public-Use With State, Total U.S. (1969-2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003. Figure 2: Age-Adjusted Prostate Cancer Mortality Rates/100,000 by Year by Race/Ethnicity Surveillance, ...

18 Prostate Cancer The prostate is an important part of a man's urogenital system which is necessary for proper bladder control and normal sexual function. Prostate cancer is the most common cancer in US men. All men are at risk . The most common risk factor is age. More than 75 percent of men diagnosed with prostate cancer are over the age of 65. Initial screening tests for prostate cancer include a digital rectal examination (DRE), in which a doctor feels the prostate to check for abnormalities, and a blood test to detect the amount of prostate specific antigen (PSA) circulating in the blood. Prostrate Cancer Incidence Occurrence of prostate cancer in Lancaster County has declined since 1990 (Figure 18). The incidence rate for the last 12 years was similar to the incidence rate for the State and the Nation (Figure ...

C A N C E R C O N S U LT M A G A Z I N E 5 R ESEARCHERS AT THE C LEVELAND C LINIC T AUSSIG C ANCER C ENTER have identified a new biomolecu- lar pathway that may account for high osteotropism, the most common com- plication in prostate cancer patients. “Preventing bone metastasis is crucial in the effective treatment of prostate cancer .” — Tatiana Byzova, Ph.D. “Despite the high incidence and serious consequences of skeletal metas- tasis in prostate cancer , the mechanisms underlying it have been poorly under- stood,” says Cancer Center researcher Tatiana Byzova, Ph.D., who headed the research team. Dr. Byzova and colleagues have identified key molecular and cellular ...

WHAT EVERY MAN SHOULD KNOW ABOUT PROSTATE CANCER Prostate cancer often has no symptoms. This is why screening is so important for all men starting as young as age 40, particularly if they are at high risk due to family history or racial background. Black men have the highest incidence of prostate cancer , followed by Hispanics. Many current guidelines specify that screening for all men should begin at age 50. Any persistent increase in PSA over time at any level, even within the normal range, should be investigated to rule out prostate cancer . If patients and doctors were to keep a PSA record or a graph, noting any changes and noting the trend over time in PSA values, countless lives would be saved. The quality of life for many men diagnosed with prostate cancer is better preserved with early detection of the disease versus diagnosis with advanced disease. Prostate cancer detected ...

WHAT EVERY MAN SHOULD KNOW ABOUT PROSTATE CANCER If someone in your family had prostate cancer or breast cancer , then you are more likely to get prostate cancer . Prostate cancer can have no signs, so it is important that you should be tested every year from the age of 50. Testing is done in two parts – 1. The PSA blood test. A PSA of 3 or more should be checked to rule out cancer . A PSA that keeps rising, even if it is still below 3, should also be checked. Prostate cancer is easier to deal with if it is caught early. 2. The DRE (digital rectal exam). This is a simple test to feel and check the prostate . If you are not given a DRE, you should ask for it to be done as it can help find cancer that can be cured. If your test results need to be looked at to rule out cancer , the first steps should be: V To check your free PSA percentage. A free ...

About prostate cancer • Prostate cancer is the second most common cause of cancer death in UK men. • It is mainly a cancer of older men. Only 1 in 20 cases occur in men under 60. • The number of new cases increased rapidly in the 1990s. This was largely because greater use of the ‘PSA test’ (see box) led to more cases of prostate cancer being detected. • A small number of men have a much higher than average risk of prostate cancer because they inherited a faulty gene from a parent. • By the age of 80, more than half of all men have cancerous changes in their prostate . However, the disease often grows very slowly without causing problems. Many men never know they have it and will die of unrelated causes. • The highest rate of prostate cancer in the world is in men of African descent. The lowest ...

• Prostate cancer is the most common cancer among American men. • Men who are older than 50 years of age, are African American, or have a brother or father with prostate cancer are more likely than other men to get prostate cancer . • In some men prostate cancer grows very slowly, and in other men it spreads quickly. • If you are at risk, talk with your doctor about the risks and benefits of tests such as a rectal exam and prostate -specific antigen (PSA) to find prostate cancer . Sample Prevention Prescriptions for Adults 181 Name: __ R X for Prevention Follow-up: _ __ __ __ Clinician’s Signature: Date: Put Prevention Into Practice Prostate Cancer

Chapter 1 Identifying Basic Realities of Prostate Cancer In This Chapter Getting a better understanding of prostate cancer Spotting prostate cancer imposters Developing a treatment plan with your doctor Coping with the effects of prostate cancer P rostate cancer is a malignant tumor that starts in your prostate . Some prostate cancers are very slow-growing, causing you no trouble unless you live a very long time. On the other hand, quick-growing prostate cancers — and I think most of the ones picked up by doctors are this kind — can kill you if the cancer spreads beyond the prostate , if the cancer isn’t diagnosed in time, or if you take no action after your diagnosis. However, you can often be cured of prostate cancer if the cancer is localized (or confined) to the prostate . I had surgery for my ...

PSA Screening for Prostate Cancer Medical Crossfire 2003 Read the full story: PSA Screening for Prostate Cancer : Addressing Counseling Controversies and Clinical Questions Medical Crossfire's Peer Exchange process allows our readers to respond with their thoughts on the topics featured in our debates. To provide your comments or position on this debate, use our Online Peer Exchange Form now. Ralph Alterowitz, MEA President of the Board Education Center for Prostate Cancer Patients; Founding Vice-Chair The National Prostate Cancer Coalition; President Venture Tech Corporation Jericho, New York Editor’s note: Mr. Alterowitz is also the coauthor of The Lovin’ Ain’t Over—The Couple’s Guide to Better Sex After Prostate Disease . O pponents to screening offer up a number of reasons ...

prostate cancer What is the prostate ? The prostate is a walnut-sized gland in the adult male?s reproductive system. It is located right below the bladder, in front of the rectum. What is prostate cancer ? Prostate cancer is a disease in which cancer cells grow in the prostate and then may spread to other parts of the body. It is the most common type of cancer found in American men, other than skin cancer . It is a slow growing form of cancer , and can be cured if detected early. What are the symptoms of prostate cancer ? The symptoms of prostate cancer are: Frequent trips to the bathroom (especially at night) Trouble going to the bathroom Pain or burning when going to the bathroom Weak or jerky urine flow Pain during ejaculation Blood in the urine or semen Frequent pain ...

1 KELOWNA PROSTATE CANCER SUPPORT & AWARENESS GROUP NEWSLETTER OKANAGAN PROSTATE RESOURCE CENTRE CANADIAN PROSTATE SOCIETY CANCER NETWORK Okanagan Prostate Resource Centre P.O. Box 1253 Suite 210A – 3001 Tutt Street, Lakefield, Ontario, Kelowna, B.C., V1Y 2H4 K0L 2H0 Phone – (250) 712-2002 Phone – (705) 652-9200 Fax – (250) 712-2004 Fax – (705) 652-0663 E-mail – oprc@silk.net http://www.cpcn.org CCS Cancer Information Line – 1-888-939-3333 Publisher / Editor – Bren Witt Newsletter available online at www.cpcn.org VOLUME 7 – ISSUE 11 – (No. 83) – JUNE 2004 ur guest speaker at the May meeting of the Kelowna Prostate Cancer Support and Awareness Group was Ms. Janice Perrino, the Director of Development for the BC Cancer Foundation in Kelowna . Janice ...

R ADIOLOGY AND R ADIATION T HERAPY O RIENTED S TUDIES 67 Hypofractionation for Prostate Cancer Radiotherapy – What Are the Issues? David J. Brenner You can’t open a radiation journal these days without someone debating the a/ß ratio for prostate cancer (1-21). Why the debate? What are the issues? What might they mean for prostate cancer radiotherapy? In bri ef, the argu- ments have gone as follows: 1. One of the main motivations for delivering a treatment in many fractions is that late sequelae are generally more sensi- tive than early effects (such as tumor control) to changes in fractionation. So increasing the number of fractions gener- ally spares late-responding tissues more than the tumor. This can be quanti fied in terms of the a/ß ratio: • A small a/ß ...

Scientific summary Prostate cancer care: improving measures of the patient experience Lead researcher: Professor Richard Baker, University of Leicester Aim To develop valid, reliable and usable measures of patient experience of prostate cancer care suitable for use in routine practice. Design 1. Interview and questionnaire survey of CSCs to establish their requirements for the measure(s) 2. Review of literature on patients’ experiences of prostate cancer care 3. Qualitative study of patients’ experiences of prostate cancer care 4. Development of a new measure from the NCPS questionnaire 5. Consensus study of the completeness of the new measure(s) 6. Question reduction through sequential pilots and elimination of redundant questions 7. Submission of the draft measure(s) to a sample of 400 patients of four CSCs to assess reliability, validity ...

Plain language summary Prostate cancer care: improving measures of the patient experience Lead researcher: Professor Richard Baker , University of Leicester Services for people with prostate cancer are undergoing reform to ensure that effective treatments are delivered quickly to the people who need them, in a way the meets the preferences of the patients themselves. The reforms involve local clinical teams in reviewing their services, making changes, and evaluating whether the changes have improved things for patients. Therefore, it is essential that clinical teams understand patients’ experiences of care, and ask patients whether changes do lead to improvements. Different methods can be used for asking patients about their experiences. For evaluating the impact of changes, the chosen method must provide accurate and reliable data. The aim of this study is to develop a measure that ...

Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18 Archangel Levi Omara-Opyene 1 , Jingxin Qiu 1 , Girish V Shah 2 and Kenneth A Iczkowski 1,3 1 Department of Pathology, Immunology, and Laboratory Medicine, The University of Florida, Gainesville, FL, USA; 2 Department of Pharmaceutical Sciences, University of Louisiana, Monroe, LA, USA and 3 Department of Pathology and Laboratory Medicine, Veterans Administration Medical Center, Gainesville, FL, USA The standard form of cell adhesion glycoprotein CD44 is a metastasis suppressor in prostate cancer . However, we previously showed by RT-PCR and Western blotting that cancer overexpresses unique CD44 variant v7–v10 isoforms. Muc18 is another cell adhesion marker reportedly overexpressed by ...

Nutrition & Prostate Cancer Natalie Ledesma, MS, RD Cancer Resource Center UCSF Comprehensive Cancer Center University of California, San Francisco Scientific evidence suggests that differences in diet and lifestyle may account in large part for the variability of prostate cancer rates in different countries [1]. Good nutrition may reduce the incidence of prostate cancer and help reduce the risk of pros- tate cancer progression. There are many studies currently being conducted to help further understand how diet and prostate cancer are related. We do know, however, that improved nutrition reduces risk of heart disease, diabetes, and obesity, and usually improves overall quality of life. It is estimated that one-third of cancer deaths in the U.S. can be attributed to diet in adulthood, including diet’s effect on obesity [2]. Additionally, ...

Status Appro ved Appro ved with Changes Ar t Director Creativ e Director Cop ywr iter Account Ex ecutiv e Client An Educational Service of the Canadian Prostate Health Council A PATIENT’S GUIDE PROSTATE CANCER AND DIET HSS ELI C04030E CPHC Pamphlet 5/14/04 12:38 PM Page 1 Station: blam Page 2 Prostate cancer is the most commonly diagnosed cancer in Canadian men. One out of 8 will develop prostate cancer during their lifetime. Prostate cancer may be curable if diagnosed early. Even when the disease is advanced, treatment may eradicate symptoms and improve survival. Medical evidence suggests that diet may influence the risk of developing prostate cancer as well as the progression of cancer in patients ...

Voice 21 February 10, 2003 PROSTATE CANCER AND THE USEFULNESS OF PSA Transformation of one or more normal prostate cells into cancer cells marks the begining of prostate cancer . Although the reasons for prostate cancer are not exactly understood, the following are considered as important risk factors (1). x Age: Age is generally considered the most important risk factor for prostate cancer . Although prostate cancer can strike younger men, the incidence of prostate cancer rises quickly after the age of 60. x Genetics: Variations and mutations in certain genes may be responsible for some increases in prostate cancer rates in families. x Diet: The most common dietary culprit implicated in increasing prostate cancer risk is a high fat diet, particularly a diet high in animal fats. x Ethinicity: Prostate cancer ...

Fox Chase Cancer Center 2003 Scientific Report 1 The Prostate Cancer Risk Assessment Program (PRAP). Bruner, Konski, Uzzo, Feigenberg, Horwitz, Mazzoni, Raysor, Hanks, a in collaboration with Hanlon, § Daly, § Greenberg, § Mirchandani b The primary objective of PRAP is to maintain a prostate cancer risk registry (PCRR) and screen- ing clinic for prostate cancer high-risk families, to strengthen our understanding of the heredi- tary-environmental processes of prostate car- cinogenesis and provide education and informed decision making as well as medical and psychosocial interventions to high-risk men. The second major objective is to study the genetic predisposition to prostate cancer and the third objective is to develop tools for primary prevention ...

About prostate cancer • Prostate cancer is the second most common cause of cancer death in UK men. • It is mainly a cancer of older men. Only 1 in 20 cases occur in men under 60. • The number of new cases appeared to increase rapidly in the 1990s.This was largely because the increasing use of the ‘PSA test’ (see box) led to more cases of prostate cancer being detected. • A small number of men are much more likely to develop prostate cancer because they have inherited a faulty gene from one of their parents. • By the age of 80, more than half of all men have cancerous changes in their prostate . However, the disease often grows very slowly without causing problems. So many men never know they have it and die of unrelated causes. • The highest rate of prostate cancer in the world is in men of African ...

76 Rogers Street Cambridge, MA 02142 Phone: (617) 475-7500 Fax: (617) 475-7501 www.therionbio.com Prostate Cancer Vaccine Patient Brochure Therion Biologics Corporation is a leader in developing therapeutic vaccines for treating cancer . The Company’s goal is to generate safe and effective therapies that improve patients’ quality of life and increase patient survival by stimulating the body’s immune system to specifically attack cancer cells. For more information about Therion, please visit our website at www.therionbio.com To see if you meet eligibility requirements, please consult your physician. General Clinical Trial Disclaimer The purpose of most clinical trials is to test new cancer treatments. Because potentially harmful side effects are not known before a trial is conducted, dose and schedule ...

What it is and How it is treated A Booklet for Patients PROSTATE CANCER : Page 2 I NTRODUCTION 1 W HAT I S C ANCER ? . 2 W HAT S HOULD I K NOW A BOUT P ROSTATE C ANCER ? . 4 D IAGNOSIS AND S TAGING T ESTS 10 T HE G LEASON S YSTEM . 11 TNM S TAGING S YSTEM 14 H OW I S P ROSTATE C ANCER T REATED ? . 16 P ROSTATECTOMY . 16 ...

Monash Commercial Pty Ltd ACN 095 891 722 Ground Floor, Administration 3b Monash University, Victoria 3168, Australia Telephone: (+61 3) 9905 9515 Facsimile: (+61 3) 9905 5030 www.moncommercial.com OPPORTUNITY PROFILE Prognostic Markers for Prostate Cancer Technology / Product: The technology involves multiple predictive markers with the potential to distinguish between slow growing and aggressive prostate cancer . Currently there are no adequate prognostic markers for prostate cancer . Future products will include: • Tissue-based diagnostic test to be used on prostate biopsy and surgical tissues • Blood-based diagnostic test to be used regularly to monitor disease status Advantages will be to identify patients who need surgical prostate removal and appropriate chemotherapy treatment, versus patients with latent cancer that can ...

Seminar article Hormonal prevention of prostate cancer Otis W. Brawley* Professor of Medicine, Oncology and Epidemiology, The Winship Cancer Institute, Emory University, Atlanta, GA, USA Abstract Prostate cancer is disease in which the mortality rate is highly variable among populations. An increasing risk with migratory changes suggests that some environmental factor or factors influence prostate cancer risk. It is well established that the prostate is hormonally influenced. Carcinogenesis is a process of malignant transformation evolving over time, involving cellular growth and division. There is evidence suggesting that androgenic influences over a period time encourages the process of prostate carcinogenesis. Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for both normal and hyperplastic growth of the ...

News Volume 6, Issue 3, June 2004 1 "MAKING PROSTATE CANCER HISTORY IN CALIFORNIA!" PRESIDENT'S MESSAGE The fight continues to restore funding for the IMPACT program, the only program of its kind in the country and one of the most deserving treatment programs in existence! CPCC has made great progress but we have not completed the battle. We have sent many Board members and patient survivors to testify before the various Senate and Assembly sub-Committees and Dr. Mark Litwin of UCLA has also testified on the importance of IMPACT and what it means to California families. We have issued a plea for funds to help defray some of our expenses in going back and forth to Sacramento and we need any help available to achieve our goals. The CPCC's IMPACT committee headed by Stan Mikkelsen, Andy Reschke, Wes Sholes ...

Golf Town Cements Three-year Commitment to The Prostate Cancer Research Foundation of Canada Toronto – May 12, 2004 Canada’s largest golf retailer – Golf Town, has committed to a three-year, national support program to raise funds for The Prostate Cancer Research Foundation of Canada as well as increase awareness for the devastating disease estimated to afflict one in eight men. “We started supporting the foundation last year because a large percentage of our customers – men between the ages of 40 and 55 – are prime candidates for the disease,” said Stephen Bebis, CEO of Golf Town Canada, and newly appointed member of The Prostate Research Foundation of Canada board of directors. “ Prostate cancer is the number one cancer threat to men in Canada,” said Bebis. Golf Town raised $70,000 for research and public education during The Prostate Research Foundation of Canada’s Prostate ...

M ANAGEMENT U PDATE VOL. 6 NO. 2 2004 REVIEWS IN UROLOGY 73 Examining the Relationship Between Obesity and Prostate Cancer Stephen J. Freedland, MD,* William J. Aronson, MD † *The Brady Urological Institute, Department of Urology, The Johns Hopkins School of Medicine, Baltimore, MD; † Department of Urology, UCLA School of Medicine, Los Angeles, CA Affecting over 30% of the population, obesity is an epidemic in the United States and is associated with multiple chronic medical problems. Obesity is also associated with numerous hormonal changes, many of which have been implicated in prostate cancer development and progression. Although, on the whole, controversy exists over whether obesity increases the risk of prostate cancer , data strongly suggest that obesity is a significant risk factor for ...

Brachytherapy for the treatment of prostate cancer November 2000 MSAC application no. 1029 Assessment report Page 2 © Commonwealth of Australia 2001 ISBN 0 642 73587 5 ISSN 1443-7120 (print) ISSN 1443-7139 (online) First printed July 2001 This work is copyright. Apart from any use as permitted under the C opyright Act 1968 no part may be reproduced by any process without written permission from AusInfo. Requests and inquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT, 2601. Electronic copies of the report can be obtained from the Medicare Service Advisory Committee’s Internet site at: http://www.health.gov.au/haf/msac Hard copies of the report can be obtained from: The Secretary Medicare ...

Title: Brachytherapy for the Treatment of Prostate Cancer - November 2000 Agency: Medicare Services Advisory Committee (MSAC) Commonwealth Department of Health and Ageing GPO Box 9848 Canberra ACT 2601 Australia http://www.msac.gov.au Reference: MSAC application 1029. Assessment report ISSN 1443-7120 Aim: To assess the safety and effectiveness of the service and under what circumstances this service should be supported with public funding. Conclusions and results: Safety Brachytherapy may offer less risk of impotence and urinary incontinence than other major treatment options for localised prostate cancer . Effectiveness There has not been a successful randomised controlled trial of the use of brachytherapy. The relative advantage of brachytherapy derives from perceived scope for potency preservation and the single session outpatient ...

prostate cancer Clinical Challenges in the Treatment of Symptomatic Patients with Advanced Disease Frans M. J. Debruyne, MD, PhD Professor and Chairman Department of Urology University Medical Center Nijmegen Nijmegen, The Netherlands Therapeutic Options by Stage for Prostate Cancer T3a XRT w/ HT P for some patients T1a WW P XRT T1b–1c P XRT HT – with or w/o P or XRT T3b XRT w/ HT T2 P XRT HT – with or w/o P or XRT D3 Chemo-therapy w/ or w/o HT T4 HT, possibly w/XRT D1.5 XRT P HT Combi- nation D1,D2 HT WW = watchful waiting P = prostatectomy XRT = radiation ...